All Insights White Paper Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Sales Operations

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    Do Pharma Companies Need To Rethink Their Sales Operations Design?

    The COVID-19 pandemic has brought about many long-term changes to the pharma industry. One area that has seen effects directly caused by COVID-19 has been in sales operations design, management, and engagement with customers due to increased access restrictions of sales reps to physicians. COVID-19 has also accelerated institutional rethinking of the level and role of direct sales forces in the pharma industry. This white paper explores why pharma companies need to explore these changes. Companies need to prepare for changing the size and objective of direct sales forces given the effects of COVID-19 and the impact of existing environmental trends highlighted by the pandemic.

    Contact us at insights@axtria.com with any questions.

    Complete the brief form to download the white paper

    Recommended insights

    Pharma Sales Operations Design White Paper

    Report

    Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

    Pharma Sales Operations Design White Paper

    White Paper

    The evolving role of sales ops in omni

    Pharma Sales Operations Design White Paper

    Industry Primer

    Digital Transformation